invoX Pharma, a biopharmaceutical company, completed the acquisition of F-star, a clinical-stage biopharmaceutical company, for $161m. “The closing of the transaction today significantly strengthens invoX’s pharmaceutical business, accelerating the build of a pipeline with a core focus on oncology and respiratory therapeutics. Most importantly, it provides the capital to ensure patients enrolled in F-star’s clinical studies will continue to have access to potentially life-saving therapies," Ben Toogood, invoX CEO.